Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention Program
Open Access
- 1 April 2008
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 57 (4), 980-986
- https://doi.org/10.2337/db07-1419
Abstract
OBJECTIVE— To determine whether baseline adiponectin levels or intervention-associated change in adiponectin levels were independently associated with progression to diabetes in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS— Cox proportional hazards analysis was used to evaluate the contribution of adiponectin and treatment-related change in adiponectin to risk of progression to diabetes. RESULTS— Baseline adiponectin was a strong independent predictor of incident diabetes in all treatment groups (hazard ratio per ∼3 μg/ml higher level; 0.61 in the lifestyle, 0.76 in the metformin, and the 0.79 in placebo groups; all P < 0.001, P = 0.13 comparing groups). Baseline differences in adiponectin between sexes and race/ethnicity groups were not reflected in differences in diabetes risk. DPP interventions increased adiponectin levels ([means ± SE] 0.83 ± 0.05 μg/ml in the lifestyle group, 0.23 ± 0.05 μg/ml in the metformin group, and 0.10 ± 0.05 μg/ml in the placebo group; P < 0.001 for increases versus baseline, P < 0.01 comparing groups). These increases were associated with reductions in diabetes incidence independent of baseline adiponectin levels in the lifestyle and placebo groups but not in the metformin subjects (hazard ratio 0.72 in the lifestyle group (P < 0.001), 0.92 in the metformin group (P = 0.18), and 0.89 in the placebo group; P = 0.02 per ∼1 μg/ml increase, P = 0.02 comparing groups). In the lifestyle group, adjusting for change in weight reduced, but did not remove, the effect of increased adiponectin. CONCLUSIONS— Adiponectin is a powerful marker of diabetes risk in subjects at high risk for diabetes, even after adjustment for weight. An increase in adiponectin in the lifestyle and placebo groups was associated with a reduction in diabetes risk. However, these changes in adiponectin were comparatively small and less strongly related to diabetes outcome than baseline adiponectin levels.Keywords
This publication has 37 references indexed in Scilit:
- Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention ProgramDiabetes, 2007
- Associations of Adiponectin Levels With Incident Impaired Glucose Metabolism and Type 2 Diabetes in Older Men and WomenDiabetes Care, 2006
- Effect of Weight Loss With Lifestyle Intervention on Risk of DiabetesDiabetes Care, 2006
- Adherence to Preventive MedicationsDiabetes Care, 2006
- Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndromeJournal of Clinical Investigation, 2006
- Mice Lacking Adiponectin Show Decreased Hepatic Insulin Sensitivity and Reduced Responsiveness to Peroxisome Proliferator-activated Receptor γ AgonistsJournal of Biological Chemistry, 2006
- Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin SensitivityJournal of Biological Chemistry, 2004
- Cloning of adiponectin receptors that mediate antidiabetic metabolic effectsNature, 2003
- Disruption of Adiponectin Causes Insulin Resistance and Neointimal FormationJournal of Biological Chemistry, 2002
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001